Expired
Lead Plaintiff Deadline
Jul 25, 2022
Choose your preferred way to stay informed of new case launches and settlement deadlines
(i) the data submitted in support of the New Drug Application ("NDA") for the Company's product candidate, Tebipenem HBr, were insufficient to obtain approval from the U.S. Food and Drug Administration ("FDA"); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero’s operations; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
In order to be eligible to join the SPRO class action lawsuit, you must have incurred a loss on shares of Spero purchased during the class period listed above.
If you suffered a loss in Spero during the relevant time frame or pursuant to the relevant offering(s), you have until July 25, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
TOP
